retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Eli Lilly's shows promising weight loss results in 3 Retatrutide for weight loss: Study

Trulicity (dulaglutide): Manufactured by Eli Lilly and FDA-approved for type 2 diabetes, Trulicity has been named in both MDL 3094 and MDL 3163 and appears in approximately one quarter of the federal GLP-1 drug lawsuits reviewed by USA TODAY

95% CI: 00.11) were associated with significantly lower fracture risk, whereas trelagliptin (a DPP-4 inhibitor) was linked to increased fracture risk (RR = 3.51

The intervention group consisted of patients who were prescribed GLP-1 RA medications, including Victoza (Liraglutide 1.8 mg), Saxenda (Liraglutide 3 mg), Ozempic (Semaglutide 1 mg), and Wegovy (Semaglutide 2.4 mg)

Author Contributions All authors reviewed, edited, and approved the final version of the manuscript

Giacosa A, Guido D, Grassi M, et al